LUX-Lung 2 and 3 cancer clinical trial James Yang
LUX Lung clinical cancer trial programme Kenneth O'Byrne
Summary of LUX Lung 1 & 2 clinical trials Lucio Crino
Summary of LUX Lung 1 clinical trial Kenneth O'Byrne
Summary of LUX Lung 2 clinical trial Kenneth O'Byrne
LUME Lung 2 clinical trial infographic
LUME-Lung 1 Infographic
LUX-Lung 3 clinical trial infographic
LUX Lung 2 clinical trial infographic
LUX Lung 1 clinical trial
LUX Lung 1 clinical trial infographic
LUX Lung 1 clinical trial fact sheet
LUX Lung 2 clinical trial
LUX Lung 2 clinical cancer trial
LUX Lung 3 clinical cancer trial
LUX Lung 4 clinical cancer trial
Lux lung 5 phase 3 clinical trial
Lux lung 6 cancer clinical trial
Lume lung 1 cancer clinical trial
Lume lung 2 cancer clinical trial
2011 clinical trials poster
Boehringer Ingelheim to commence Lux Lung 3 study investigating the role of BIBW 2992* as first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutations
Press release LUME-Lung 1+2 November 2008
Source for healthcare professionals: www.inoncology.com* BIBF 1120, BIBW 2992 and BI 6727 are investigational compounds. Their safety and efficacy have not yet been fully established.